FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281285503> ?p ?o ?g. }

• W4281285503 abstract "Abstract Introduction Head-to-head studies comparing COVID-19 mRNA vaccine effectiveness in immunocompromised individuals, who are vulnerable to severe disease are lacking, as large sample sizes are required to make meaningful inferences. Methods This observational comparative effectiveness study was conducted in closed administrative claims data from the US HealthVerity database (December 11, 2020-January 10, 2022, before omicron). A 2-dose mRNA-1273 versus BNT162b2 regimen was assessed for preventing medically-attended breakthrough COVID-19 diagnosis and hospitalizations among immunocompromised adults. Inverse probability of treatment weighting was applied to balance baseline characteristics between vaccine groups. Incidence rates from patient-level data and hazard ratios (HRs) using weighted Cox proportional hazards models were calculated. Results Overall, 57,898 and 66,981 individuals received a 2-dose regimen of mRNA-1273 or BNT161b2, respectively. Among the weighted population, mean age was 51 years, 53% were female, and baseline immunodeficiencies included prior blood transplant (8%-9%), prior organ transplant (7%), active cancer (12%-13%), primary immunodeficiency (25%-26%), HIV (20%-21%), and immunosuppressive therapy use (60%-61%). Rates per 1,000 person-years (PYs; 95% confidence intervals [CI]s) of breakthrough medically-attended COVID-19 were 25.82 (23.83-27.97) with mRNA-1273 and 30.98 (28.93, 33.18) with BNT162b2 (HR, 0.83; 95% CI, 0.75-0.93). When requiring evidence of an antigen or polymerase chain reaction test before COVID-19 diagnosis, the HR for medically-attended COVID-19 was 0.78 (0.67-0.92). Breakthrough COVID-19 hospitalization rates per 1,000 PYs (95% CI) were 3.66 (2.96-4.51) for mRNA-1273 and 4.68 (3.91-5.59) for BNT162b2 (HR, 0.78; 0.59-1.03). Utilizing open and closed claims for outcome capture only, or both cohort entry/outcome capture, produced HRs (95% CIs) for COVID-19 hospitalization of 0.72 (0.57-0.92) and 0.66 (0.58-0.76), respectively. Conclusions Among immunocompromised adults, a 2-dose mRNA-1273 regimen was more effective in preventing medically-attended COVID-19 in any setting (inpatient and outpatient) than 2-dose BNT162b2. Results were similar for COVID-19 hospitalization, although statistical power was limited when using closed claims only. Study Registration NCT05366322" @default.
• W4281285503 created "2022-05-24" @default.
• W4281285503 creator A5002503150 @default.
• W4281285503 creator A5002735756 @default.
• W4281285503 creator A5009268823 @default.
• W4281285503 creator A5023622250 @default.
• W4281285503 creator A5028715121 @default.
• W4281285503 creator A5033475333 @default.
• W4281285503 creator A5033532580 @default.
• W4281285503 creator A5035942809 @default.
• W4281285503 creator A5043170740 @default.
• W4281285503 creator A5059798670 @default.
• W4281285503 creator A5060879630 @default.
• W4281285503 creator A5067348293 @default.
• W4281285503 date "2022-05-19" @default.
• W4281285503 modified "2023-10-17" @default.
• W4281285503 title "Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults in the United States" @default.
• W4281285503 cites W2110818436 @default.
• W4281285503 cites W2126049444 @default.
• W4281285503 cites W2800966522 @default.
• W4281285503 cites W3111255098 @default.
• W4281285503 cites W3117489874 @default.
• W4281285503 cites W3137814380 @default.
• W4281285503 cites W3153508314 @default.
• W4281285503 cites W3166152977 @default.
• W4281285503 cites W3167039701 @default.
• W4281285503 cites W3168278554 @default.
• W4281285503 cites W3183558279 @default.
• W4281285503 cites W3184620427 @default.
• W4281285503 cites W3186535828 @default.
• W4281285503 cites W3208046866 @default.
• W4281285503 cites W3209139070 @default.
• W4281285503 cites W3215143364 @default.
• W4281285503 cites W4200235080 @default.
• W4281285503 cites W4205128723 @default.
• W4281285503 cites W4205483821 @default.
• W4281285503 cites W4206624662 @default.
• W4281285503 cites W4210960512 @default.
• W4281285503 cites W4220661611 @default.
• W4281285503 cites W4220979761 @default.
• W4281285503 cites W4232249876 @default.
• W4281285503 doi "https://doi.org/10.1101/2022.05.13.22274960" @default.
• W4281285503 hasPublicationYear "2022" @default.
• W4281285503 type Work @default.
• W4281285503 citedByCount "2" @default.
• W4281285503 countsByYear W42812855032023 @default.
• W4281285503 crossrefType "posted-content" @default.
• W4281285503 hasAuthorship W4281285503A5002503150 @default.
• W4281285503 hasAuthorship W4281285503A5002735756 @default.
• W4281285503 hasAuthorship W4281285503A5009268823 @default.
• W4281285503 hasAuthorship W4281285503A5023622250 @default.
• W4281285503 hasAuthorship W4281285503A5028715121 @default.
• W4281285503 hasAuthorship W4281285503A5033475333 @default.
• W4281285503 hasAuthorship W4281285503A5033532580 @default.
• W4281285503 hasAuthorship W4281285503A5035942809 @default.
• W4281285503 hasAuthorship W4281285503A5043170740 @default.
• W4281285503 hasAuthorship W4281285503A5059798670 @default.
• W4281285503 hasAuthorship W4281285503A5060879630 @default.
• W4281285503 hasAuthorship W4281285503A5067348293 @default.
• W4281285503 hasBestOaLocation W42812855031 @default.
• W4281285503 hasConcept C120665830 @default.
• W4281285503 hasConcept C121332964 @default.
• W4281285503 hasConcept C126322002 @default.
• W4281285503 hasConcept C187212893 @default.
• W4281285503 hasConcept C207103383 @default.
• W4281285503 hasConcept C23131810 @default.
• W4281285503 hasConcept C2781413609 @default.
• W4281285503 hasConcept C2908647359 @default.
• W4281285503 hasConcept C3018095205 @default.
• W4281285503 hasConcept C44249647 @default.
• W4281285503 hasConcept C61511704 @default.
• W4281285503 hasConcept C71924100 @default.
• W4281285503 hasConcept C99454951 @default.
• W4281285503 hasConceptScore W4281285503C120665830 @default.
• W4281285503 hasConceptScore W4281285503C121332964 @default.
• W4281285503 hasConceptScore W4281285503C126322002 @default.
• W4281285503 hasConceptScore W4281285503C187212893 @default.
• W4281285503 hasConceptScore W4281285503C207103383 @default.
• W4281285503 hasConceptScore W4281285503C23131810 @default.
• W4281285503 hasConceptScore W4281285503C2781413609 @default.
• W4281285503 hasConceptScore W4281285503C2908647359 @default.
• W4281285503 hasConceptScore W4281285503C3018095205 @default.
• W4281285503 hasConceptScore W4281285503C44249647 @default.
• W4281285503 hasConceptScore W4281285503C61511704 @default.
• W4281285503 hasConceptScore W4281285503C71924100 @default.
• W4281285503 hasConceptScore W4281285503C99454951 @default.
• W4281285503 hasLocation W42812855031 @default.
• W4281285503 hasOpenAccess W4281285503 @default.
• W4281285503 hasPrimaryLocation W42812855031 @default.
• W4281285503 hasRelatedWork W1970383787 @default.
• W4281285503 hasRelatedWork W1999374750 @default.
• W4281285503 hasRelatedWork W2089045987 @default.
• W4281285503 hasRelatedWork W2275480158 @default.
• W4281285503 hasRelatedWork W2313076522 @default.
• W4281285503 hasRelatedWork W2409957712 @default.
• W4281285503 hasRelatedWork W2900720613 @default.
• W4281285503 hasRelatedWork W3095306390 @default.
• W4281285503 hasRelatedWork W4238089809 @default.
• W4281285503 hasRelatedWork W4241346791 @default.
• W4281285503 isParatext "false" @default.

• next